The well-known CRC-specific markers, such as APC, KRAS, BRAF, HER2, and TP53 somatic mutations and the microsatellite stability status, are also critical factors for tumor classification and optimal therapy decision [13,14,15]. This evidence concerns the gene KRAS and colorectal carcinoma.